| Title |
The Use of Medical Marijuana in Cancer
|
|---|---|
| Published in |
Current Oncology Reports, May 2016
|
| DOI | 10.1007/s11912-016-0530-0 |
| Pubmed ID | |
| Authors |
Shauna M. Birdsall, Timothy C. Birdsall, Lucas A. Tims |
| Abstract |
The use of medical marijuana in cancer care presents a dilemma for both patients and physicians. The scientific evidence is evolving, yet much of the known information is still insufficient to adequately inform patients as to risks and benefits. In addition, evidence-based dosing and administration information on medical marijuana is lacking. Medical marijuana is now legal, on some level, in 24 states plus the District of Columbia, yet is not legal on the federal level. This review addresses the current state of the research, including potential indications, risks and adverse effects, preliminary data on anticancer effects, as well as legal and quality issues. A summary of the clinical trials underway on medical marijuana in the oncology setting is discussed. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 217 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 215 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 32 | 15% |
| Researcher | 29 | 13% |
| Student > Master | 22 | 10% |
| Student > Ph. D. Student | 20 | 9% |
| Student > Postgraduate | 13 | 6% |
| Other | 42 | 19% |
| Unknown | 59 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 45 | 21% |
| Agricultural and Biological Sciences | 16 | 7% |
| Nursing and Health Professions | 16 | 7% |
| Biochemistry, Genetics and Molecular Biology | 13 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 5% |
| Other | 45 | 21% |
| Unknown | 71 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2022.
All research outputs
#2,962,569
of 23,130,383 outputs
Outputs from Current Oncology Reports
#89
of 899 outputs
Outputs of similar age
#52,828
of 334,319 outputs
Outputs of similar age from Current Oncology Reports
#4
of 15 outputs
Altmetric has tracked 23,130,383 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 899 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,319 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.